MultiStem: Completed Phase II enrollment

Athersys said Pfizer completed enrollment in a double-blind, placebo-controlled, international Phase II trial of IV MultiStem. The trial was targeting up to 128 patients. MultiStem is also in Phase II testing to treat ischemic stroke and inflammatory bowel disease (IBD) and Phase I testing for acute myocardial infarction (MI) and graft-versus-host disease (GvHD). Last week, MultiStem received Orphan Drug designation in the EU to prevent GvHD, for which a Phase II/III trial is slated to start next year. The product has Orphan Drug designation in the U.S for mucopolysaccharidosis I (MPS-I, Hurler's syndrome) and GvHD. ...